Physician profile
Perry Kaplan
NPI 1346201944
$3,248.74
in general payments reported to CMS, 2019-2025
20 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $275 · 2021: $1,051 · 2022: $298 · 2023: $415 · 2024: $842 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,398.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,021.92 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $399.26 | 2021-2022 | |
| Stryker Corporation | $389.72 | 2021-2025 | Everest Spinal System |
| Kyowa Kirin, INC. | $228.33 | 2020-2021 | |
| Lilly USA, LLC | $199.15 | 2023-2024 | Mounjaro |
| Merck Sharp & Dohme LLC | $144.65 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $121.38 | 2023 | Eliquis |
| W. L. Gore & Associates, INC. | $116.01 | 2021 | |
| Boston Scientific Corporation | $107.51 | 2023 | Ranger |
| Actelion Pharmaceuticals US, INC. | $106.06 | 2019 | |
| Idorsia Pharmaceuticals US INC | $104.08 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.19 | 2019-2021 | |
| Ethicon US, LLC | $79.08 | 2019 | |
| Almatica Pharma LLC | $25.88 | 2021-2022 | |
| Amarin Pharma, INC. | $25.71 | 2019-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $25.36 | 2020 | |
| Mckesson Medical-Surgical, INC. | $20.00 | 2021 | |
| Exact Sciences Corporation | $16.86 | 2023 | Cologuard Collection Kit |
| Novo Nordisk INC | $14.59 | 2021 | |
| Astellas Pharma US INC | $12.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Perry Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.